<DOC>
	<DOCNO>NCT02808780</DOCNO>
	<brief_summary>The purpose study compare incidence lymphoma adult participant moderate-to-severe ulcerative colitis treat Simponi versus treat thiopurines .</brief_summary>
	<brief_title>An Observational Prospective Long-term Exposure Registry Adult Patients With Moderate-to-Severe Ulcerative Colitis</brief_title>
	<detailed_description>This observational prospective long-term exposure registry adult participant moderate-to-severe ulcerative colitis . Two cohort , Simponi-exposed cohort comparator cohort treat thiopurines , enrol study . Approximately 6,000 participant plan enrollment , 3,000 participant Simponi-exposed cohort 3,000 participant comparator cohort . Participants receive treatment routine clinical setting prescribed physician . After enrollment , 10-year follow-up period , participant may stop ulcerative colitis treatment regimen switch new treatment regimen . Lymphoma incidence primarily assess questionnaire sent investigator obtain complete medical information case . An expert panel medical specialist extensive experience lymphoma convene validate case lymphoma . Besides assess incidence lymphoma , long-term safety evaluate capture adverse event interest serious adverse event .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Have moderatetosevere ulcerative colitis least 3 month ' duration prior enrollment , confirm endoscopy time past For enrollment Simponiexposed cohort meet one following : 1 . The participant currently receive Simponi , 2 . The participant continue receive Simponi participation ulcerative colitis study , 3 . The participant schedule receive Simponi within 30 day enrollment For Comparator cohort : 1 . The participant currently receive thiopurines , receive least 12 consecutive week therapy prior registry entry 2 . Participant must receive approve biologic agent , include Simponi , investigational agent enrollment 3 . Participant may receive biologics Simponi investigational agent prior enrollment Participants treat Simponi thiopurines Participants previous diagnosis lymphoma hematologic malignancy time prior enrollment Participants currently receive investigational biologic agent Simponi Participants condition , opinion investigator , participation registry would best interest participant could prevent , limit , confound protocolspecified assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Simponi ( Golimumab )</keyword>
	<keyword>Thiopurines</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Malignancies</keyword>
</DOC>